The Alpha Omega Cohort

A cohort of Dutch patients with a history of myocardial infarction

The Alpha Omega Cohort emerged from the Alpha Omega Trial, a 3-year intervention study of omega-3 fatty acids after myocardial infarction.
Read more about the study population
4837 patients
with history of myocardial infarction
60-80 years of age
most receiving state-of-the-art drugs

From trial to cohort

The Alpha Omega Trial was designed to examine whether major cardiovascular events could be prevented by low doses of omega-3 fatty acids (incorporated in margarines) in 4,837 Dutch patients with a history of myocardial infarction.

Patients were enrolled from 2002-2006 and the trial was completed in 2009. Follow-up of the Alpha Omega Cohort for cause-specific mortality is still ongoing.

Cohort findings

A selection of the main findings within the cohort.
higher risk

Current smokers have a 72% higher mortality risk than never smokers.

lower risk

Patients who drink more than 4 cups of coffee a day have a 32% lower risk of mortality from ischemic heart disease than patients who drink 0-2 cups a day.

higher risk

Accelerated kidney function decline is related to a 4 times higher mortality risk.

lower risk

Healthy eating is related to a 30% lower mortality risk.

lower risk

Replacing saturated with unsaturated fatty acids is related to a 63% lower risk of mortality from ischemic heart disease.

See our main cohort findings and infographics

A study by Wageningen University & Research

The Alpha Omega Cohort is coordinated by researchers at Wageningen University, The Netherlands. The trial phase was sponsored by the Dutch Heart Foundation, National Institutes of Health, Unilever R&D (margarine development and distribution) and Wageningen University.


We welcome collaborations and data sharing with other researchers. If you are interested, visit our collaboration page and get in touch.

Information for researchers